CERS vs. LUNG, TCMD, INO, KIDS, ATRI, ANIK, OSUR, UTMD, WST, and ALGN
Should you be buying Cerus stock or one of its competitors? The main competitors of Cerus include Pulmonx (LUNG), Tactile Systems Technology (TCMD), Inovio Pharmaceuticals (INO), OrthoPediatrics (KIDS), Atrion (ATRI), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), and Align Technology (ALGN). These companies are all part of the "medical" sector.
Pulmonx (NASDAQ:LUNG) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
Pulmonx currently has a consensus target price of $16.33, suggesting a potential upside of 125.29%. Cerus has a consensus target price of $3.83, suggesting a potential upside of 114.15%. Given Cerus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than Cerus.
Cerus has higher revenue and earnings than Pulmonx. Cerus is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cerus had 1 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Cerus and 2 mentions for Pulmonx. Cerus' average media sentiment score of 1.59 beat Pulmonx's score of 0.61 indicating that Pulmonx is being referred to more favorably in the media.
Pulmonx has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Cerus received 538 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 72.26% of users gave Cerus an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
Cerus has a net margin of -19.27% compared to Cerus' net margin of -80.46%. Cerus' return on equity of -48.09% beat Pulmonx's return on equity.
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 3.4% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Pulmonx and Cerus tied by winning 9 of the 18 factors compared between the two stocks.
Get Cerus News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
